TL;DR
Two deaths involving counterfeit versions of investigational weight-loss drug retatrutide were reported to the FDA, according to CBS News. Separately, Novo Nordisk plans to discontinue the weight-loss injection Saxenda in early 2027 as sales decline.
Two deaths involving counterfeit versions of retatrutide, an investigational weight-loss drug, were reported to the U.S. Food and Drug Administration, according to CBS News, while Novo Nordisk said it plans to discontinue its weight-loss injection Saxenda in early 2027 because of declining sales. The reports involve different drugs and developments: retatrutide is not approved, while Saxenda is an established prescription treatment that the company plans to withdraw from sale.
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The deaths were described in an Oct. 13 endocrinology news roundup as cases tied to counterfeit versions of retatrutide that had been reported to the FDA. Retatrutide is still investigational, meaning it has not received approval as a weight-loss medication. The source roundup cited CBS News but did not provide details about the people who died, where the products came from, or what role the counterfeit products may have played in the deaths.
In a separate development, Novo Nordisk plans to discontinue liraglutide (Saxenda) for weight management in early 2027. The company attributed the decision to declining sales. The supplied report does not specify when sales will end in individual markets, whether remaining product will be available during a phase-out, or what alternatives the company recommends for patients using Saxenda.
The roundup also noted that lawsuits are alleging severe adverse events associated with GLP-1 receptor agonists, citing NPR. Those are allegations in ongoing litigation, not findings established by the report. The source material does not link the lawsuits to either the counterfeit retatrutide deaths or Novo Nordisk’s decision about Saxenda.
Counterfeit Drugs and Saxenda Plans
The reported deaths point to a distinct safety concern: counterfeit medicines can differ from regulated products, and the report does not establish that the deaths resulted from properly manufactured or approved retatrutide. Because retatrutide remains investigational, consumers cannot assume that products sold under that name outside authorized research are the same as a trial drug. The source material provides no specific product-testing findings or confirmed cause of death.
Saxenda’s planned discontinuation matters to people who use it for weight management and to clinicians who prescribe it. The change is planned for early 2027, not reported as an immediate stop, but patients may need time to discuss continuity of care with their prescribers. The report gives declining sales as the reason and does not say that the decision followed a new safety finding.
The two developments should not be conflated. Counterfeit retatrutide reports concern unapproved products; Saxenda is a different drug, and its planned withdrawal is a commercial decision according to the company. Keeping those distinctions clear helps readers assess what is known without treating separate drug stories as evidence of a single safety trend.
Products Worth Considering
Oral-B iO3 Rechargeable Electric Toothbrush with 3 Cleaning Modes, Pressure Sensor, 2 Brush Heads and Travel Case, White
Therabody WaveRoller Vibrating Foam Roller
BowFlex Results Series 552 SelectTech Adjustable Dumbbell
As an affiliate, we earn on qualifying purchases.
Retatrutide and Saxenda Differ
The Oct. 13 report was a short roundup of developments in endocrinology, not a detailed investigation into the deaths or a full announcement about Saxenda’s market withdrawal. It also covered research and policy items, including new World Health Organization guidance recommending against weight-loss drugs or bariatric surgery for children younger than 10. Those items are separate from the two developments addressed here.
Retatrutide is investigational, whereas liraglutide is marketed as Saxenda for weight management. The roundup described the retatrutide products in the death reports as counterfeit; it did not say the deaths occurred in a clinical trial. Nor did it report that the FDA had concluded the drug itself caused the deaths. Saxenda’s discontinuation, by contrast, was attributed to declining sales by Novo Nordisk, with early 2027 given as the intended timing.
The roundup’s mention of lawsuits over GLP-1 drugs is also a separate point. Lawsuit allegations are not proof of causation, and the source did not report a court ruling or regulatory conclusion resolving those claims.
“Two recent deaths tied to counterfeit versions of retatrutide, an investigational weight-loss medication, were reported to the FDA.”
— CBS News, as cited in the October 13 endocrinology roundup
Death Reports Lack Case Details
The supplied report does not identify the people who died, the locations or dates of the cases, the source or composition of the counterfeit products, or the medical cause of death. It says the cases were reported to the FDA, but does not describe an agency investigation, a causal determination, or any regulatory action. Those details remain unconfirmed in the material provided.
For Saxenda, the report does not specify the exact end date, how the planned discontinuation will be carried out across markets, or whether other products will remain available. It also does not identify any new safety concern behind the decision; declining sales is the reason given.
The lawsuits mentioned in the roundup remain allegations as described. The source provides no information on specific plaintiffs, case outcomes, or findings that would establish whether a particular medicine caused an adverse event.
FDA and Company Updates Ahead
Further information from the FDA or reporting that identifies the counterfeit products and case circumstances could clarify what is known about the two reported deaths. Until then, the available source supports only that the reports were submitted to the agency; it does not establish causation.
Novo Nordisk’s planned early-2027 discontinuation is the next stated milestone for Saxenda. The report does not give a more precise schedule or describe transition arrangements for patients. Anyone currently prescribed the medication should discuss individual treatment plans with a qualified health professional rather than infer from the roundup that they should stop taking it.
Updates on the GLP-1 lawsuits may clarify the status of the allegations, but the roundup provides no court dates or expected rulings. The factual distinction remains: reported counterfeit-product deaths, a planned commercial discontinuation of a separate drug, and unresolved legal claims.
Key Questions
Did the FDA confirm that retatrutide caused the deaths?
The supplied report says two deaths involving counterfeit retatrutide were reported to the FDA. It does not say the agency confirmed that retatrutide caused the deaths or provide a cause-of-death finding.
Is retatrutide an approved weight-loss drug?
No. The report describes retatrutide as investigational. It does not provide details about authorized clinical trials or the products involved in the reported deaths.
When is Saxenda expected to be discontinued?
Novo Nordisk plans to discontinue Saxenda in early 2027, according to the roundup. A precise date and market-by-market schedule were not provided.
Is Saxenda being discontinued because of safety concerns?
The stated reason is declining sales. The source does not report that the planned discontinuation is due to a new safety finding.
Are the GLP-1 lawsuit claims proven?
No such finding is reported in the supplied material. It describes ongoing lawsuits alleging severe adverse events; allegations should not be treated as established causation or a court ruling.
Source: rss
